Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 7/20 | 0.41 |
| ▸ | CNR2 | P34972 | 7/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18737455 | 0.89 | CNR1 (0.43) | LMNATP53CNR1CNR2TRPA1 | |
| SCHEMBL22420143 | 0.86 | CNR1 (0.48) | LMNATP53CNR1CNR2TRPA1 | |
| SCHEMBL20585498 | 0.86 | LMNA (0.50) | LMNATP53CNR1CNR2TRPA1 | |
| SCHEMBL20216157 | 0.85 | CNR2 (0.42) | LMNATP53CNR1CNR2TRPA1 | |
| SCHEMBL18897192 | 0.78 | LMNA (0.39) | LMNATP53CNR1CNR2TRPA1 | |
| SCHEMBL9004525 | 0.78 | CNR2 (0.46) | LMNATP53CNR1CNR2TRPA1 | |
| SCHEMBL10965656 | 0.77 | CNR1 (0.38) | LMNATP53CNR1CNR2TRPA1 | |
| SCHEMBL10965664 | 0.77 | CNR1 (0.38) | LMNATP53CNR1CNR2TRPA1 | |
| SCHEMBL21166388 | 0.77 | CNR2 (0.42) | LMNATP53CNR1CNR2TRPA1 | |
| SCHEMBL13766053 | 0.76 | CNR1 (0.40) | LMNATP53CNR1CNR2TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-9663524-B2 | Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors | CELGENE CAR LLC (BM) | 2017-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | LMNA 2907/4885TP53 106/4885CNR1 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.